You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
Though its point-of-care revenues fell, the firm's clinical laboratory sales for the third quarter rose 44 percent over the prior-year quarter
The system, which automates the process of performing blood cell differentials, was cleared by the US Food and Drug Administration last month.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
HeartGenetics offers a range of genetic tests and services including ones for general wellness, cardiovascular conditions, and pharmacogenetics.
The company said that it has received CE marks for two additional SARS-CoV-2 tests, including one that detects the virus and influenza A/B.
The partners aim to refine a saliva-based SARS-CoV-2 test developed by Yale that received Emergency Use Authorization from the FDA earlier this year.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
Abbott has terminated its prior $5 billion credit agreement also with JP Morgan reached in November 2018.
Life science product revenues nearly doubled, offsetting a continuing slide in the firm's diagnostics revenues.
The firm signed a deal with Zotal to be exclusive Israeli distributor of the test, which measures proteins in patient blood to detect diabetic kidney disease.
For the three months ended Sept. 30, the firm said that total revenues fell to $1.2 million from $1.3 in the year-ago quarter with OVA1 volumes essentially flat.
Despite the dramatic growth in overall testing revenue, the company's core oncology testing revenue dropped significantly quarter-over-quarter.
A negative preliminary decision regarding reimbursement for the company's flagship colon cancer screening test in the US remains an issue for the company.
The firm said that overall cartridge volumes in Q3 were back at pre-pandemic levels, and that it is on track to achieve targeted 30 percent growth for full-year 2020.
The company's goal is to help laboratories and smaller diagnostic firms accelerate test development and provide end-to-end test design assistance.
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.